Phase II clinical evaluation of Gd-EOB-DTPA: Dose, safety aspects, and pulse sequence

Radiology

Volumn 199, Issue 1, 1996, Pages 177-183

  Reimer, Peter ^a   Rummeny, Ernst J ^a   Shamsi, Kohkan ^b   Balzer, Thomas ^b   Daldrup, Heike E ^a   Tombach, Bernd ^a   Hesse, Tanja ^a   Berns, Thomas ^a   Peters, Peter E ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Contrast media, experimental studies; Gadolinium; Liver, MR; Magnetic resonance (MR), contrast enhancement

Indexed keywords

CONTRAST MEDIUM; ECHOVIST; GADOLINIUM; GADOLINIUM ETHOXYBENZYL PENTETATE; PENTETIC ACID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HUMAN; IMAGE ANALYSIS; LIVER INJURY; LIVER METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029986898     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.199.1.8633143     Document Type: Article

References (24)

1. Lauffer RB, Vincent AC, Padmanabhan S, et al. Hepatobiliary MR contrast agents: 5-substituted iron-EHPG derivatives. Magn Reson Med 1987; 4:582-590.
2. Brasch RC. New directions in the development of MR imaging contrast media. Radiology 1992; 183:1-11.
3. Weissleder R, Bogdanov A, Papisov M. Drug targeting in magnetic resonance imaging. Magn Reson Q 1992; 8:55-63.
4. Reimer P, Rummeny EJ, Daldrup HE, et al. Clinical results with Resovist: a phase 2 clinical trial. Radiology 1995; 195:489-496.
5. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U. Preclinical evaluation of Gd EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992; 183:59-64.
6. Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, Vogler H, Frenzel T, Gries H. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 1992; 22:233-237.
7. Mühler A, Clement O, Vexler V, Berthezene Y, Rosenau W, Brasch RC. Hepatobiliary enhancement with Gd-EOB-DTPA: comparison of spin-echo and STIR imaging for detection of experimental liver metastases. Radiology 1992; 184:207-213.
8. Clement O, Mühler A, Vexler VS, et al. Evaluation of radiation-induced liver injury with MR imaging: comparison of hepatocellular and reticuloendothelial contrast agents. Radiology 1992; 185:163-168.
9. Marchal G, Zhang X, Ni P, van Hecke P, Baert AL. Comparison between Gd-DTPA, Gd-EOB-DTPA, and Mn-DPDP in induced HCC in rats: a correlation study of MR imaging, microangiography, and histology. Magn Reson Imaging 1993; 11:665-674.
10. Mühler A, Freise CE, Kuwatsuru R, et al. Acute liver rejection: evaluation with cell-directed MR contrast agents in a rat transplantation model. Radiology 1993; 186:139-146.
11. Clement O, Mühler A, Vexler V, Berthezene Y, Brasch RC. Gadolinium-EOB-DTPA, a new liver specific MR contrast agent: kinetic and enhancement patterns in normal and cholestatic rats. Invest Radiol 1992; 27:612-619.
12. Clement O, Mühler A, Vexler V, et al. Comparison of Gd-EOB-DTPA and Gd-DTPA for contrast-enhanced MR imaging of liver tumors. JMRI 1993; 3:1-7.
13. Hamm B, Staks T, Mühler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195:785-792.
14. Mahfouz AE, Hamm B, Taupitz M, Wolf KJ. Hypervascular liver lesions: differentiation of focal nodular hyperplasia from malignant tumors with dynamic gadolinium-enhanced MR imaging. Radiology 1993; 186:133-138.
15. Armitage P, Berry G, eds. Statistical methods in medical research. 2nd ed. Oxford, England: Blackwell Scientific, 1987.
16. Pavone P, Patrizio G, Buoni C, et al. Comparison of Gd-BOPTA with Gd-DTPA in MR imaging of rat liver. Radiology 1990; 176:61-64.
17. Shtern F, Garrido L, Compton CC, Swiniarski JK, Lauffer RB, Brady TJ. MR imaging of blood-borne liver metastases in mice: contrast enhancement with Fe-EHPG. Radiology 1991; 178:83-89.
18. Ni Y, Marchai G, Yu J, et al. Experimental liver cancers: Mn-DPDP-enhanced rims in MR-microangiographic-histologic correlation study. Radiology 1993; 188:45-51.
19. Vogl TJ, Pegios W, MacMahon C, et al. Gadobenate dimeglumine: a new contrast agent for MR imaging - preliminary evaluation in healthy volunteers. AJR 1992; 158: 887-892.
20. Bernardino ME, Young SW, Lee JKT, Weinreb JC. Hepatic MR imaging with Mn-DPDP: safety, image quality, and sensitivity. Radiology 1992; 183:55-58.
21. Hamm B, Vogl T, Branding G, et al. Focal liver lesions: MR imaging with Mn-DPDP: initial clinical results in 40 patients. Radiology 1992; 182:167-174.
22. Rummeny EJ, Ehrenheim C, Gehl HB, et al. Manganese-DPDP as a hepatobiliary contrast agent in the MR imaging of liver tumors: results of clinical phase II trials in Germany including 141 patients. Invest Radiol 1992; 26:879-886.
23. 14C-labelled Mn-DPDP in rats and dogs. Presented at the 10th Annual Scientific Meeting and Exhibition of the European Society for Magnetic Resonance in Medicine and Biology, Rome, Italy, 1993; 251.
24. Ni Y, Marchai G, Lukito G, Yu J, Mühler A, Baert AL. MR imaging evaluation of liver enhancement by Gd-EOB-DTPA in selective and total bile duct obstruction in rats: correlation with serologic, microcholangiographic, and histologic findings. Radiology 1994; 190:753-758.